Literature DB >> 7522201

Menstrual and hormone patterns in women treated with high-dose cisplatin and bleomycin.

F Maneschi1, P Benedetti-Panici, G Scambia, M G Salerno, G D'Agostino, S Mancuso.   

Abstract

Menstrual and hormone patterns were investigated in 10 fertile women (median age 37, range 25-43 years) with locally advanced cervical cancer treated with neoadjuvant chemotherapy (CT). CT consisted of two cycles of high-dose cisplatin (CDDP, 40 mg/m2, Days 1 to 4) and bleomycin (B, 15 mg/m2, Days 1 and 8) separated by an interval of 21 days. Menstrual patterns before and during CT were recorded. FSH, LH, estradiol, and progesterone were assayed on the day that treatment was begun, after 2 and 4 days of CDDP administration, and weekly between and after the two cycles. Hormone assays during the first week of CT showed no significant change in hormone levels. After the first course of CT, five patients showed hypergonadotrophic amenorrhea and five patients maintained menses, two showing ovulatory and three showing follicular phase hormone patterns. After the second course of CT, one more patient become amenorrheic, and endocrine follow-up showed that two patients maintained hypergonadotrophic amenorrhea, four with hypergonadotrophic amenorrhea had a return of hormone levels to the follicular range of 7-9 weeks after, three maintained follicular phase hormone patterns until operation, and one ovulated. Gonadal dysfunction should be included among the side effects of high-dose CDDP and B regimens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522201     DOI: 10.1006/gyno.1994.1221

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.

Authors:  Russell C Langan; Peter A Prieto; Richard M Sherry; Daniel Zlott; John Wunderlich; Gyorgy Csako; Rene Costello; Donald E White; Steven A Rosenberg; James C Yang
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

2.  The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: Gender related differences in rat model.

Authors:  Fatemeh Eshraghi-Jazi; Mehdi Nematbakhsh; Hamid Nasri; Ardeshir Talebi; Maryam Haghighi; Zahra Pezeshki; Tahereh Safari; Farzaneh Ashrafi
Journal:  J Res Med Sci       Date:  2011-11       Impact factor: 1.852

3.  Vitamin e is a nephroprotectant agent in male but not in female in a model of Cisplatin-induced nephrotoxicity.

Authors:  Sima Jilanchi; Mehdi Nematbakhsh; Mehrnoosh Bahadorani; Ardeshir Talebi; Fatemeh Eshraghi-Jazi; Azam Mansouri; Farzaneh Ashrafi
Journal:  ISRN Nephrol       Date:  2013-06-23

Review 4.  Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy.

Authors:  Hoon Jang; Kwonho Hong; Youngsok Choi
Journal:  Int J Mol Sci       Date:  2017-06-07       Impact factor: 5.923

Review 5.  Ovarian damage from chemotherapy and current approaches to its protection.

Authors:  N Spears; F Lopes; A Stefansdottir; V Rossi; M De Felici; R A Anderson; F G Klinger
Journal:  Hum Reprod Update       Date:  2019-11-05       Impact factor: 15.610

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.